Ensuring children's inclusion in the Bundibugyo Ebola response: Striving to do better this time

Q: What does this research mean for the field?

A multi-country, adaptive platform randomized trial is designed to evaluate the effect of new and repurposed therapies on all-cause mortality in patients with filovirus disease, aiming to improve the inclusion of children in outbreak responses. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Mike Kalmus Eliasz; Michael Adeyemi-Lawal; Lauren D’Mello Guyett; Daniela Manno; Bruce Myango; Paula Reges; Neal Russell

doi:10.1371/journal.pgph.0007117

September 2, 2026PLOS Global Public HealthOpen Access

Ensuring children's inclusion in the Bundibugyo Ebola response: Striving to do better this time

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Assesses 28-day mortality from novel therapies in acute filovirus disease, highlighting the necessity of pediatric inclusion in outbreak responses.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Eliasz et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd3c76b95aff0620eae41 https://doi.org/10.1371/journal.pgph.0007117

View Full Paper

Ask AI

Bookmark

Share

Ensuring children's inclusion in the Bundibugyo Ebola response: Striving to do better this time

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Ensuring children's inclusion in the Bundibugyo Ebola response: Striving to do better this time

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading